🎉 M&A multiples are live!
Check it out!

Xilio Therapeutics Valuation Multiples

Discover revenue and EBITDA valuation multiples for Xilio Therapeutics and similar public comparables like Pharming, Galapagos, and Benevolent AI.

Xilio Therapeutics Overview

About Xilio Therapeutics

Xilio Therapeutics Inc is a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology (I-O) therapies with the goal of significantly improving outcomes for people living with cancer without the systemic side effects of current I-O treatments. The company is using its proprietary platform to advance a pipeline of novel, tumor-activated clinical and preclinical I-O molecules that are designed to optimize the therapeutic index by localizing anti-tumor activity within the tumor microenvironment, including tumor-activated cytokines and antibodies (including bispecifics) and immune cell engagers (including tumor-activated cell engagers and tumor-activated effector-enhanced cell engagers).


Founded

2020

HQ

United States of America
Employees

64

Website

xiliotx.com

Financials

LTM Revenue $17.9M

LTM EBITDA -$42.9M

EV

-$10.2M

Valuation Multiples

Multiples.vc

Sign up to see

Valuation Multiples for 10K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

Xilio Therapeutics Financials

Xilio Therapeutics has a last 12-month revenue of $17.9M and a last 12-month EBITDA of -$42.9M.

In the most recent fiscal year, Xilio Therapeutics achieved revenue of $6.3M and an EBITDA of -$58.0M.

Xilio Therapeutics expects next 12-month revenue of  XXX    and NTM EBITDA of  XXX

See Xilio Therapeutics valuation multiples based on analyst estimates

Xilio Therapeutics P&L

FY 2023 FY 2024 FY 2025 LTM NTM
Revenue n/a $6.3M XXX XXX XXX
Gross Profit n/a n/a XXX XXX XXX
Gross Margin NaN% NaN% XXX XXX XXX
EBITDA -$77.2M -$58.0M XXX XXX XXX
EBITDA Margin -Infinity% -914% XXX XXX XXX
Net Profit -$88.2M -$76.4M XXX XXX XXX
Net Margin -Infinity% -1204% XXX XXX XXX
Net Debt n/a n/a XXX XXX XXX

Financial data powered by Morningstar, Inc.

Xilio Therapeutics Stock Performance

As of April 15, 2025, Xilio Therapeutics's stock price is $1.

Xilio Therapeutics has current market cap of $37.0M, and EV of -$10.2M.

See Xilio Therapeutics trading valuation data

Xilio Therapeutics Stock Data

EV Market Cap Price 1D Price 1M Price 3M Price 12M EPS
-$10.2M $37.0M XXX XXX XXX XXX $-0.88

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

Sign Up

Xilio Therapeutics Valuation Multiples

As of April 15, 2025, Xilio Therapeutics has market cap of $37.0M and EV of -$10.2M.

Xilio Therapeutics's trades at -0.6x LTM EV/Revenue multiple, and 0.2x LTM EBITDA.

Analysts estimate Xilio Therapeutics's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See valuation multiples for Xilio Therapeutics and 10K+ public comps

Xilio Therapeutics Financial Valuation Multiples

FY 2024 FY 2025E FY 2026E FY 2027E
EV -$10.2M XXX XXX XXX
EV/Revenue -1.6x XXX XXX XXX
EV/EBITDA 0.2x XXX XXX XXX
P/E -0.6x XXX XXX XXX
P/E/Growth n/a XXX XXX XXX
EV/FCF 0.6x XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get Xilio Therapeutics Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

Sign Up

Xilio Therapeutics Valuation Multiples

Xilio Therapeutics's NTM/LTM revenue growth is 181%

Xilio Therapeutics's revenue per employee for the last fiscal year averaged $0.1M, while opex per employee averaged $1.0M for the same period.

Over next 12 months, Xilio Therapeutics's ratio of sales and marketing spend to revenue is estimated to be  XXX , while its R&D spend to revenue to be  XXX .

Analysts estimate Xilio Therapeutics's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See operational valuation multiples for Xilio Therapeutics and other 10K+ public comps

Xilio Therapeutics Operational Valuation Multiples

FY 2024 NTM FY 2025E FY 2026E FY 2027E
Revenue Growth Infinity% XXX XXX XXX XXX
EBITDA Margin -914% XXX XXX XXX XXX
EBITDA Growth -25% XXX XXX XXX XXX
Rule of 40 (SaaS-only) -734% XXX XXX XXX XXX
Revenue per Employee $0.1M XXX XXX XXX XXX
Opex per Employee $1.0M XXX XXX XXX XXX
S&M Expenses to Revenue n/a XXX XXX XXX XXX
G&A Expenses to Revenue 391% XXX XXX XXX XXX
R&D Expenses to Revenue 650% XXX XXX XXX XXX
Opex to Revenue 1040% XXX XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics
Pharma Analytics
Private Equity
ERP Software
Developer Tools
Consumer SaaS
Streaming Platforms

Xilio Therapeutics Public Comps

See public comps and valuation multiples for Drug Development & Therapeutics and Vaccines & Immunotherapies comps
EV/Revenue EV/EBITDA
2025E 2026E 2027E 2025E 2026E 2027E
Julphar XXX XXX XXX XXX XXX XXX
Benevolent AI XXX XXX XXX XXX XXX XXX
Galapagos XXX XXX XXX XXX XXX XXX
Pharming XXX XXX XXX XXX XXX XXX
Vivoryon Therapeutics XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX

Valuation data powered by FactSet, Inc.

Xilio Therapeutics M&A and Investment Activity

Xilio Therapeutics acquired  XXX companies to date.

Last acquisition by Xilio Therapeutics was  XXXXXXXX, XXXXX XXXXX XXXXXX . Xilio Therapeutics acquired  XXXXXXXX for  XXX (EV/Revenue multiple of  XXX ).

See M&A valuation multiples

Latest Acquisitions by Xilio Therapeutics

Acquired Company EV EV/Revenue EV/EBITDA
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX

Get Verified M&A Valuation Multiples

Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.

Sign Up

About Xilio Therapeutics

When was Xilio Therapeutics founded? Xilio Therapeutics was founded in 2020.
Where is Xilio Therapeutics headquartered? Xilio Therapeutics is headquartered in United States of America.
How many employees does Xilio Therapeutics have? As of today, Xilio Therapeutics has 64 employees.
Who is the CEO of Xilio Therapeutics? Xilio Therapeutics's CEO is Dr. Rene Russo, Pharm.D..
Is Xilio Therapeutics publicy listed? Yes, Xilio Therapeutics is a public company listed on NAS.
What is the stock symbol of Xilio Therapeutics? Xilio Therapeutics trades under XLO ticker.
When did Xilio Therapeutics go public? Xilio Therapeutics went public in 2021.
Who are competitors of Xilio Therapeutics? Similar companies to Xilio Therapeutics include e.g. Julphar, Benevolent AI, Galapagos, Pharming.
What is the current market cap of Xilio Therapeutics? Xilio Therapeutics's current market cap is $37.0M
What is the current revenue of Xilio Therapeutics? Xilio Therapeutics's last 12-month revenue is $17.9M.
What is the current EBITDA of Xilio Therapeutics? Xilio Therapeutics's last 12-month EBITDA is -$42.9M.
What is the current EV/Revenue multiple of Xilio Therapeutics? Current revenue multiple of Xilio Therapeutics is -0.6x.
What is the current EV/EBITDA multiple of Xilio Therapeutics? Current EBITDA multiple of Xilio Therapeutics is 0.2x.
Is Xilio Therapeutics profitable? Yes, Xilio Therapeutics is EBITDA-positive (as of the last 12 months).

Join Now Or Talk To Us

Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.